› News Archive

› Events Archive

EVENTS

“WHO-ILAR COPCORD Stage II Education on Treatment of Autoimmune Diseases, a One-day International Symposium”
Saturday, May 21, 2005, JW Marriott Hotel Jakarta, Indonesia

› About WHO-ILAR COPCORD [click here]

› Poster & Invitation [Download click here]

› Program Symposium & Presentation Files

› Organizing Committee [click here]

Breakthrough in the Treatment of Autoimmune Diseases by the SBP-6-IMNs, i.e., Lupus Nephritis and RF+ RA - Remission achieved in 2-4 months

After COPCORD Stage I Community-based Epidemiological Surveys are completed after 25 years in 19 developing countries world wide , the question arise "What Next?"

COPCORD Stage II Intervention comprising Education and Treatment are very hard to get Education moving. Education are ongoing in Bangladesh for Chronic Low Back Pain and in your center in Pune India. Completed Arthritis Community Education in Indonesia showed only increased knowledge of arthritis in the subjects compared with age, sex, and education matchedf controls.

COPCORD Stage II Treatment of Rheumatoid Factor Positive Rheumatoid Arthritis (RF+ RA) after 10 and 7 years pilot studies were spread to other developing countries. Within 1 year 5 countries in 8 centers officially participated. Confirmed reports revealed that this treatment Protocol have been applied in 2 centers in Beijing and 1 center Guangzhou, China, private practitioners and private clinics in India. By request the protocol has been sent to Buenos Ares, Argentina.

Burden of Disease of RF+ RA is obviously reduced when Remission is achieved in 2-4 months, Remission maintained with oral drugs in 5.5-7.5 months, and in those Immunosuppressant-naive and < grade 2 erosion(s) obtained Remission without Drug (a FDA terminology).

The protocol will spread around the world very fast without COPCORD patronage in particular the private practitioners, because patients with RF+ RA will be running to these private centers. The reasons are that they cannot afford the Biologic Response Modifiers for lifetime such as Infliximab (Remicade), Enbrel (Etanercept), Anakinra (Kineret), Adalimumab (Humira), and Rituxumab (Mabthera) in developing countries.

The Preliminary Program for an One-day International Symposium May 21, 2005, in Jakarta, will discuss the outcome of RF+ RA and Lupus Nephritis after treatment with the SBP-4-IMNs, SBP-5-IMNs, and SBP-6-IMns. At last COPCORD Stage II Therapy can do something for the patients with Rheumatic Disease in developing countries.
 

  Email This Page   Print This Page